Kornimate/medical-research-clean huggingface dataset:
elastography in thyroid nodules

Conditions: Nodular Goiter; Thyroid Cancer

Summary: nodular goiter is a highly prevalent disease in iodine-deficient areas. usually nodule assessment includes ultrasonography (us) and fine-needle aspiration (fna), but some benign nodules can hardly be distinguished from carcinomas. elastography measures tissue elasticity using sonography, as malignancy is related to stiffness of solid organs. the investigators have designed a study to evaluate the diagnostic accuracy of elastography in nodular goiter. consecutive patients will be assessed using us, fna and elastography; the latter will be compared with cytology. specificity, sensitivity, and predictive values will be calculated.

aims: primary aim: to evaluate the diagnostic accuracy of elastography in thyroid nodules from a low-risk of thyroid cancer population. secondary aim: to evaluate the usefulness of elastography to detect carcinomas in thyroid nodules with indeterminate fna. patient selection: inclusion criteria: * age \> 18 yr. * recruitment in endocrinology clinics. * nodular goiter. * multinodular goiter with dominant nodule \> 1 cm. exclusion criteria: * toxic nodules * non-accessible nodules to us or fna * cystic nodules * nodules with calcifications in egg rind * contraindication for fna

Eligibility criteria:
inclusion criteria: * age \> 18 yr. * recruitment in endocrinology surgery. * nodular goiter. * multinodular goiter with dominant nodule \> 1 cm. exclusion criteria: * toxic nodules * non-accessible nodules to us or fna * cystic nodules * nodules with calcifications in egg rind * contraindication of fna

Keywords: elastography thyroid nodule fine-needle aspiration
effect of acupuncture and diet modification on amenorrheain female athlete triad

Conditions: Female Athlete Triad

Summary: the present study will be designed to investigate the effect of acupuncture and diet modification using soy products on amenorrhea in female athlete triad. for this purpose this study will be carried out on sixty female athletes participating gymnastics. they will be recruited from sports medicine specialized center in nasr city, their ages will range from 17 to 25 years old and their bmi will be \< 20 kg/m2 .

the subjects will be divided into three groups equal in number, matched for measured variable: group (a): acupuncture only will be used in this group for 30 minutes, three times per week for twelve weeks. the acupuncture needles were inserted in points located on the abdomen. group (b): this group will receive only the diet modification contains soy products (phytoestrogen) as 100 milliliter soy milk and 100 grams soy beans daily in the morning as a breakfast alone to ensure its absorption, this dose had been taken for 12 weeks. group (c): this group will receive both acupuncture therapy for 30 minutes, three times per week for 12 weeks and diet modification contains soy products as 100 milliliter soy milk and 100 grams soy beans daily in the morning for 12 weeks.

Eligibility criteria:
inclusion criteria: * all patients suffering from athletic amenorrhea. * their age will be ranged from 17-25 years old. * their body mass index will be less than 18.5 kg/m2. * no history of previous pregnancies. * no history of any pathological disease causing amenorrhea. * they are medically stable and consented to participate in the study. exclusion criteria: * patients with gynecological diseases that may cause amenorrhea. * patients using contraceptive pills. * patients using hormonal treatment. * patients using induction of ovulation methods. * patients following any other diet modification method. * patients who receive any drug with side effect of amenorrhea.

Keywords: sports injury female athlete triad acupuncture
placental learning model for neurovascular microsurgery for the management of intracranial aneurysms

Conditions: Intracranial Aneurysm

Summary: training in microsurgical techniques for the management of intracranial aneurysms is carried out during the practical training of the des in neurosurgery and during the continuous training of neurosurgeons according to the indications of the patients of the department. currently, the recent increase in indications for endovascular treatment compared to surgical indications has led to a decrease in surgical indications and in the experience of neurosurgeons. however, there are still surgical indications that are often complex situations that neurosurgeons must overcome with a specific simulation approach. there are different simulation models for the treatment of intracranial aneurysms. the small animal (rodent) model has the disadvantage of being poorly suited to the reproduction of intracranial aneurysms (different extracranial vessel walls, too small intracerebral vessel caliber) and of being constraining to the establishment. the computerized stimulator model which has the advantage of being able to reproduce the anatomy of a patient but whose haptic sensitivity performance is difficult to reproduce for very fine movements, it is not very accessible because it is expensive. the placental model uses a fresh human placenta, the appearance of the vessels of which is very similar to those found intracerebrally, and dilations on their walls can be performed with a pediatric urinary catheter.


Eligibility criteria:
inclusion criteria: * woman over the age of 18; * placenta considered as surgical waste intended for incineration; with a negative infectious status verified during pregnancy follow-up * woman who did not express her opposition, after information, to the reuse of her placenta for educational purposes to improve the practical training of future neurosurgeons. exclusion criteria: * subject who expressed their opposition to participating in the study * subject under guardianship or curatorship * subject under safeguard of justice

Keywords: intracranial aneurysm placental learning model neurovascular microsurgery aneurysm
point of care evaluation of high-sensitivity cardiac troponin

Conditions: Acute Coronary Syndrome

Summary: in this observational research project the investigators wish to test new technologies that could allow them to either detect or rule out heart attacks earlier. currently, when a patient attends the emergency department with symptoms that could be due to a heart attack, the patient has a blood test taken from a vein in the arm. this is sent to a laboratory to measure the level of a protein called troponin that is released from the heart when it is damaged. doctors and nurses use the level of troponin measured in that blood sample, along with a tracing of the heart and an assessment of symptoms, to decide whether the patient is having a heart attack. on average, it takes about 2 hours from the patient arriving at hospital to the doctor or nurse receiving the blood test result so they can make this diagnosis. a device has been designed that can measure troponin by using a drop of blood from a finger prick with the result available in around 10 minutes. this means that if a patient is having a heart attack we can diagnose it earlier and give them treatment. previous studies have also showed that the majority of patients who attend hospital with chest pain ultimately do not have a heart attack. with this new device the investigators hope to be able to reassure these patients that their symptoms are not due to a heart attack, so the clinical team can concentrate on finding out what else could be causing their chest pain, and ultimately discharge them earlier. the investigators aim to find the best way to use this new device and look at the impact this device has on the length of time from sample to diagnosis and time spent in hospital.


Eligibility criteria:
inclusion criteria: * presenting to hospital with symptoms of suspected acute coronary syndrome * age 18 years and over exclusion criteria: * patients with st-segment elevation on the electrocardiogram * patients presenting with an out-of-hospital cardiac arrest * patients unable or unwilling to give informed consent * patients unable or unwilling to comply with study protocol * previous enrolment in this study
paraorbital-occipital electric stimulation in patients with optic neuropathy (bct_optnerve)

Conditions: Visual Impairment

Summary: non-invasive brain stimulation can increase cortical excitability in the visual system, but it is not known if this is of clinical value. the investigators now assessed if repetitive, transcranial alternating current stimulation (rtacs) can improve visual field size in patients with optic nerve damage. the investigators hypothesized that rtacs would improve visual functions with the defective visual field sectors of the visual field (primary outcome measure).

exploratory, randomized, controlled study

Eligibility criteria:
inclusion criteria: * residual vision * patients with optic nerv lesion * lesion age at least 6 months * stable visual field defect exclusion criteria: * electric or electronic implants such as pace maker * any metal artefacts in head and truncus * epilepsia * photosensitive epilepsy as determines by eeg * autoimmune illnesses in acute stage * mental diseases such e.g. schizophrenia etc. * diabetes causing diabetic retinopathy * addiction * high blood pressure * unstable or high level intraocular pressure (i.e. \> 27 mmhg) * retinitis pigmentosa * pathological nystagmus * presence of an un-operated tumor or tumor recidive
a pilot study of shockwave therapy in hsp

Conditions: Hereditary Spastic Paraplegia

Summary: this is a pilot study of the efficacy, safety, and tolerability of shockwave therapy for the treatment of spasticity in hereditary spastic paraplegia.

this is a pilot study investigating the efficacy, safety, and tolerability of extracorporeal shockwave therapy (eswt) for the treatment of lower-extremity spasticity in the setting of hereditary spastic paraplegia (hsp). 8 participants will be treated with shockwave therapy targeting sites of maximal spasticity in the lower extremities for 3 sessions at a rate of once per week. participants will fill out baseline questionnaires assessing their overall wellbeing and function prior to treatment session 1, and will complete follow-up questionnaires at visit 2, visit 3, a phone call within 7 days of visit 3, and 8 weeks after initial visit. total time enrolled in the study will be 8 weeks

Eligibility criteria:
inclusion criteria: 1. over the age of 18 2. diagnosis of genetically-confirmed hsp 3. score of 2, 3 or 4 on the plsfrs walking question 4. 30 days stable dosages of oral spasticity medications prior to screening and throughout study participation 5. able to come to site for treatment sessions 6. able to understand all study procedures exclusion criteria: 1. diagnosis of any other neurological disorder that may impact gait 2. lower motor neuron (lmn) disease or combined umn and lmn 3. non-ambulatory or requiring two-person assistance for any functional ambulation on most days 4. less than 3 months of symptoms 5. have received swt within the past 3 months 6. prior botulinum toxin injection within 3 months or planning to receive botulinum toxin injections during the study participation for spasticity management 7. presence of an intra-thecal baclofen pump 8. women who are pregnant. this is due to the fact that pregnancy will reduce participants activity after the treatment and the safety concerns related to shockwave treatment. 9. patients with neuropathy affecting sensation to pain 10. patients with a known underlying cardiac disease that could be affected by shockwave therapy 11. concomitant intake of another clinical trial or other off-label experimental treatments that might influence study outcomes 12. presence of unstable psychiatric disease, cognitive impairments, or dementia impairing study participation 13. presence of other chronic neurological diseases such as alzheimer's parkinson's, stroke, or multiple sclerosis 14. personal history of narcotic overuse for chronic pain or substance abuse or dependence 15. contraindications for eswt, including local skin breakdown, infection, malignancy or other soft tissue pathology at sites of planned treatment.
the beijing longitudinal disability survey in community elderly

Conditions: Ageing; Disability; Cognitive Impairment; Frailty; Intrinsic Capacity

Summary: the goal of this observational study is to establish the prospective cohort of the beijing longitudinal disability survey in community elderly (blindsce) to explore the high-risk factors and preventive interventions for disability and cognitive impairment among community-dwelling adults aged 65 years and over. the main question it aims to answer is: * what are the high-risk factors able to predict the incidence and advance of disability and cognitive impairment in community-dwelling adults aged 65 years and over? * what are the categories of function and cognitive performance trajectory in community-dwelling adults aged 65 years and over?

blindsce is a community-based prospective cohort study that includes individuals aged 65 and over from urban and rural areas in beijing. participants will provide detailed demographic information and undergo multifactorial questionnaires, disability measurements, cognitive assessments, other disability-related outcomes, and clinical biochemical measures. the study has started recruitment and enrollment in 2023 and will follow-up once every 1-2 year. this work consists of three steps as follows. first, by collecting baseline and follow-up data of participants, we plan to establish a community-dwelling elderly database in beijing. second, high-risk factors can be pre-screening based on this cross-sectional analysis. third, longitudinal data was used to develop the prediction model and trajectory analysis for disability and cognitive impairment.

Eligibility criteria:
inclusion criteria: * community-dwelling adults aged 65 years or older who reside in beijing. * participants who sign an institutionally approved informed consent. exclusion criteria: * participants with severe mental disorders and serious medical conditions preventing study investigation * participants undergoing long-term professional treatment for physical function and cognitive functioning, such as hospitalization or rehabilitation.

Keywords: ageing disability cognitive impairment community cohort
interaction study of clopidogrel 300/75 mg given alone or concomitantly with pantoprazole 80 mg in healthy subjects

Conditions: Healthy

Summary: primary objective: * assess the effects of clopidogrel (300 mg loading dose followed by 4 days 75 mg/day) on adenosine diphosphate (adp)-induced platelet aggregation when given concomitantly with pantoprazole 80 mg/day compared to given alone in healthy male subjects * compare the pharmacokinetic profiles of clopidogrel active metabolite when clopidogrel is given either alone or concomitantly with pantoprazole secondary objective: * compare the pharmacokinetic profiles of clopidogrel when clopidogrel is given either alone or concomitantly with pantoprazole

the total study duration per subjects is 8 - 9 weeks broken down as follows: * screening: 2 to 21 days before the first dosing * period clopidogrel/placebo: 7 days including 5 days treatment * period clopidogrel/placebo + pantoprazole: 14 days including 12 days treatment * washout between periods: at least 14 days after last dosing with respect to clopidogrel treatment * end of study: 7 to 10 days after the last dosing

Eligibility criteria:
inclusion criteria: healthy male subject: * as determined by medical history, physical examination including vital signs and clinical laboratory tests: * with a body weight between 50 kg and 95 kg and with a body mass index (bmi) between 18 and 30 kg/m² exclusion criteria: * evidence of inherited disorder of coagulation/hemostasis functions * smoking more than 5 cigarettes or equivalent per day * abnormal hemostasis screen * unability to abstain from intake of any drug affecting hemostasis throughout the whole study duration * any contraindication to clopidogrel and/or pantoprazole the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
inspiratory muscle endurance of adults

Conditions: Healthy Volunteers

Summary: the aim of this study is to determine the reference value ranges for healthy adults of the incremental threshold load test, which evaluates respiratory muscle endurance.

since respiratory muscles are used in daily life at the submaximal level, evaluation of their endurance is more meaningful functionally. in addition, evaluation of endurance with respiratory muscle strength is effective in determining respiratory muscle dysfunction. failure to routinely evaluate respiratory muscle endurance, which is one of the main components of respiratory muscle function, may lead to failure to identify respiratory muscle dysfunction in early stage respiratory patients who have not yet developed muscle strength loss. however, normal value ranges have not been determined for the respiratory muscle endurance test. determining the normal value ranges for this test will help determine muscle fatigue and investigate the physiological course in respiratory diseases.

Eligibility criteria:
inclusion criteria: * being between the ages of 18-35 * not having any disease * not exercising regularly * not smoking exclusion criteria: * having a respiratory disease * have heart disease * have a neuromuscular disease * have scoliosis * having had thoracic surgery * having experienced the respiratory muscle endurance protocol before
prp vs prp plus igf for patellar tendinosis

Conditions: Tendinopathy; Patellar Ligament; Platelet-Rich Plasma

Summary: the purpose of this study is to compare two different platelet-rich plasma (prp) injections for patellar tendinosis. aim: to perform a randomized, double blinded study comparing the clinical effect of prp versus prp + concentrated insulin-like growth factor (igf) in patients with patellar tendinosis.

introduction/background: patellar tendinosis is a frustrating ailment commonly encountered in sports medicine. treating this condition continues to be a significant challenge for sports medicine physicians. the tendinosis lesion is characterized by collagen disorganization and increased ground substance. one method of treating this problem is using platelet rich plasma (prp), which is a concentration of platelets from the patient's own blood that provides a high dose of growth factors aimed at stimulating tendon healing. these injections have been used extensively to treat many tendon disorders including patellar tendinosis. several studies have demonstrated the safety and efficacy of using prp to treat patellar tendinosis. one growth factor that is known to be helpful in tendon healing is insulin-like growth factor (igf). however, igf is not found in prp but rather in the free plasma that is spun off during the prp processing. this free plasma or platelet poor plasma (ppp) is typically discarded but it is a known source of igf. we have shown that concentrating ppp in the fda cleared plasmax device yields an increased concentration of insulin-like growth factor (igf). local igf injections into the patellar tendon have demonstrated improved tendon healing, but the effect on clinical outcomes has never been studied in a controlled fashion. research design: double blinded randomized comparative trial. detailed study procedures: 38 patients will be randomly assigned to a treatment arm. 19 patients will receive platelet rich plasma (prp) and 19 patients will receive prp plus concentrated igf. patient will be blinded to their treatment, but treatment team will not. prp will be prepared according to standard sterile procedures out of view of the patient to ensure patients are adequately blinded. the injecting physician will not be blinded to randomization scheme.

Eligibility criteria:
inclusion criteria: * \>6 weeks of symptomatic patellar tendinosis * unilateral or bilateral * 18 yrs of age or older * active in sport and exercise at least 3x / week * able to take time away from sport (for healing and rehabilitation phase after procedure) * failed at least 6 weeks of guided rehabilitation (under the supervision of either a certified athletic trainer or physical therapist) * minimum tegner activity level of 4 exclusion criteria: * steroid injection in target knee in the last 3 months * prp in the target knee in the last 6 months * no other cellular treatments in index knee (bone marrow, amniotic suspensions) last 1 year * participation in any experimental device or drug study within 1 year before screening visit * oral or im steroids for last 3 months * dry needling of patellar tendon in last 6 months
the effect of autologous hematopoietic stem cell transplantation on the lower urinary tract function related to qol in ms patients

Conditions: Multiple Sclerosis; Lower Urinary Tract Symptoms

Summary: academic research project monitoring the effect of autologous hematopoietic stem cell transplantation (ahsct) on multiple sclerosis-associated lower urinary tract symptoms.

an observational study (academic research project) monitoring the effect of autologous hematopoietic stem cell transplantation (ahsct) in patients with multiple sclerosis (ms) on lower urinary tract symptoms occurrence. the main goal is to observe the influence of this treatment modality on changes in the quality of life. secondary endpoints are the changes in the urodynamic parameters and lower urinary tract occurrence. the investigators assume the inclusion of a minimum of 20 patients with ahsct and 20 patients in the control group with other disease-modifying therapy (dmt).

Eligibility criteria:
inclusion criteria: * subjects (male and female) aged 18 and over * subjects with signed informed consent * subjects able to undergo examination according to the protocol * patients indicated by neurologists to perform ahsct or treated with the closest similar disease-modifying therapy (control group) exclusion criteria: * subjects with a history of bladder cancer * subjects after previous pelvic radiotherapy * subjects with evidence of microscopic or macroscopic hematuria * subjects with a history of bladder reconstruction (augmentation cystoplasty, catheterizable stoma), subjects after cystectomy * treatment with botulinum toxin injection into the bladder wall in the last 12 months * patients in whom the pharmacological treatment of the lower urinary tract has not been stable in the last 3 months and is being adjusted * patients whose lower urinary tract symptoms are not stable for at least 3 months * patients with a permanent catheter * patients with recurrent symptomatic lower urinary tract infections - 3 or more episodes of infection in the last 12 months * subjects with tubal urine screening-proven bacteriuria * patients with acute lower urinary tract inflammation at baseline * subjects with painful bladder syndrome * patients after sacral neuromodulation * patients with severe pelvic organ prolapse * patients after radical pelvic surgery * patients with a life expectancy of less than 5 years at the time of inclusion in the study * lactating women, pregnant women, women trying to get pregnant, or sexually active women without a tendency to use safe contraception (hormonal-based oral contraceptives, injectable contraception, hormonally active implants, sexual abstinence, vasectomy in a partner) * subjects who participated in another study in the previous 90 days

Keywords: multiple sclerosis lower urinary tract symptoms autologous hematopoietic stem cell transplantation disease-modifying therapy quality of life